Ignite Creation Date:
2025-12-24 @ 11:08 PM
Ignite Modification Date:
2025-12-25 @ 8:41 PM
Study NCT ID:
NCT07165769
Status:
RECRUITING
Last Update Posted:
2025-12-18
First Post:
2025-09-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-09-04
Start Date Type:
ACTUAL
Primary Completion Date:
2028-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2025-09-03
First Submit QC Date:
None
Study First Post Date:
2025-09-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-11
Last Update Post Date:
2025-12-18
Last Update Post Date Type:
ESTIMATED